# Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

> **NCT00765661** · PHASE2 · COMPLETED · sponsor: **Veloxis Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- Kidney Failure
- Renal Failure

## Interventions

- **DRUG:** Tacrolimus (Tacro™)
- **DRUG:** Prograf

## Key facts

- **NCT ID:** NCT00765661
- **Lead sponsor:** Veloxis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2015-05-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765661, "Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00765661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*